IFN- β 1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms
- 2 October 2001
- journal article
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 21 (10) , 809-812
Abstract
Recently, mRNA encoding soluble isoforms of CD28 and CTLA-4 have been described in human lymphocytes. We demonstrate that interferon-beta1a (IFN-beta1a) can enhance the expression of these transcripts in human mononuclear cells. Because soluble CD28 and CTLA-4 molecules might affect T cell activation, our findings suggest an additional means whereby IFN-beta therapy might exert its immunomodulatory effects in multiple sclerosis (MS).Keywords
This publication has 23 references indexed in Scilit:
- Expression and function of the costimulatory molecules B7-1 (CD80) and B7-2 (CD86) in an in vitro model of the human blood–brain barrierJournal of Neuroimmunology, 2001
- A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cellsEuropean Journal of Immunology, 1999
- Identification of Three Alternatively Spliced Variants of Human CD28 mRNABiochemical and Biophysical Research Communications, 1999
- Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.Journal of Clinical Investigation, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995
- Treatment of Murine Lupus with CTLA4IgScience, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- CTLA-4 is a second receptor for the B cell activation antigen B7.Journal of Experimental Medicine, 1991
- Antigen presentation by brain microvessel smooth muscle and endotheliumJournal of Neuroimmunology, 1990